This Research & Innovation Action under Horizon Europe will fund multinational, academic-led Phase I/II trials of novel, targeted treatments and companion diagnostics tailored for children (0-14 years) and adolescents (15-19 years) with cancers that have poor prognosis. Projects must demonstrate safety, preliminary efficacy, reduced acute/long-term toxicity, and generate open-science datasets for the future UNCAN.eu platform.
Eligibility Criteria:
- Consortia of at least three independent legal entities from Horizon Europe Member States or Associated Countries
- Academic sponsors with paediatric oncology trial experience and access to patient populations
- Inclusion of multidisciplinary partners (clinicians, data scientists, SSH experts, patient advocates, SMEs, regulators)
- Trial protocols addressing socio-economic, biological, sex/gender stratification and companion diagnostic development
- Commitment to metadata registration in the European Health Data Space and open-science tool sharing via UNCAN.eu
Funding Details:
- Action Type: HORIZON-RIA (Research & Innovation Action)
- Total Budget: 25 000 000 EUR
- Indicative Grants: 4 grants of 6 000 000 EUR –8 000 000 EUR each
- Grant Model: Single-stage, lump-sum Horizon-AG-LS
Deadline:
Submit via the EU Funding & Tenders Portal by 16 September 2025, 17:00 Brussels time.
Where to Apply & More Info:
- EU Funding & Tenders Portal – search HORIZON-MISS-2025-02-CANCER-04